Molecular Templates Inc (MTEM) Share Price

MTEM MOMSTER PLAY UNDERWAY

MTEM...81...-12% Today...looking for Red to Green move here...🥳

$MTEM Gain 211% #DDAmanda Video Analysis - #1 Stock Screener / Scanner

Questions/Support: 760 702-2009 - Hans@DDAmanda.com



Z

Every reason to bet your house on a stock in these crooked days! What a scam man!

The recent 8k confirms it’s winding down its operation… LOL

Read this horse-shit =In a turbulent market environment, Molecular Templates Inc. (NASDAQ:MTEM) stock has plummeted to a 52-week low, reaching a distressing price level of $0.31. This significant downturn reflects a staggering 1-year change with the company's stock value eroding by -94.83%. Investors have watched with concern as the biopharmaceutical company, known for its innovative therapeutic products, grapples with the pressures that have led to this concerning milestone. The sharp decline over the past year underscores the volatility and challenges faced by the biotech sector at large, as well as company-specific hurdles that have impacted investor confidence and stock performance.

"In other recent news, Molecular Templates, Inc. held its annual stockholder meeting, marking several significant developments. The meeting led to the election of Corsee Sanders, Ph.D., to the Board of Directors as a Class II director for a term of three years. The ratification of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024, was another major resolution passed. Additionally, the compensation of the company's named executive officers was approved on an advisory basis. These developments reflect the latest in the company's governance and financial oversight. It's important to note that these are recent developments and may shape the company's strategic direction. As always, investors are advised to consider analyst projections and assessments in their decision-making process."

InvestingPro Insightshttps://za.investing.com/news/company-news/mtem-stock-touches-52week-low-at-031-amid-market-challenges-93CH-3370204

$MTEM pic.twitter.com/tk7KUPfnhi— THE FINAL COUNTDOWN (@THIS_TIME_X) October 16, 2024

I guess ppl don’t read filings LOL

RIP

MTEM under $3

Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement

$MTEM - Up 12% Pre-Market/ Current Price $0.53
Announces Up to $40 Million Private Placement Offering

Looking good! https://last10k.com/sec-filings/mtem/0001171843-23-003314.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=mtem

Looks good got a starter $$$$

Molecular Templates Announces IND Acceptance by FDA for MT-8421 ETB Program Targeting CTLA-4

Source: GlobeNewswire Inc.

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, has received clearance by the United States Food and Drug Administration (“FDA”) following review of its Investigational New Drug Application (“IND”) to proceed for clinical testing of its novel MT-8421 ETB program targeting CTLA-4 in patients with relapsed/refractory solid tumors previously exposed to checkpoint inhibitors.
“MT-8421 represents a novel approach to target CTLA-4 in a wholly distinct manner from the current monoclonal antibody approaches. MT-8421 was designed to eliminate CTLA-4-expressing Tregs in the tumor microenvironment (“TME”) through a direct cell-kill mechanism independent of the effector cell presence that antibodies rely upon while not effecting Tregs in the periphery, the major mechanism of antibody-mediated autoimmune toxicity,” said Eric Poma, Chief Executive Officer and Chief Scientific Officer of MTEM.

Preclinical data from MT-8421 showed that in a transgenic mouse model expressing human CTLA-4 and bearing syngeneic subcutaneous tumors, MT-8421 treatment depleted immune suppressive Tregs in the TME but not in the periphery. MT-8421 was well tolerated in a non-human GLP primate toxicology study and achieved serum levels well-above projected IC50 concentrations for Tregs in the TME. MTEM expects to initiate a first-in-human phase I study with MT-8421 by mid-year 2023 at a starting dose of 32 mcg/kg.

About Molecular Templates
Molecular Templates is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. Our proprietary drug platform technology, known as engineered toxin bodies, or ETBs, leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer.

Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Molecular Templates disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Molecular Templates may identify forward-looking statements. Examples of such statements include, but are not limited to, statements regarding the safety or potential efficacy of Molecular Templates’ drug or biologic candidates; the prospects of CTLA-4 targeting therapies as a potential treatment; statements relating to the development of MT-8421; the expected timing of initiating and completing enrollment of cohorts and conducting the planned Phase I study of MT-8421; and Molecular Templates’ belief that its proprietary biologic drug platform technology, or ETBs, provides for a differentiated mechanism of action for cancer.

Forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual events or results may differ materially from those discussed in the forward-looking statements as a result of various factors including, but not limited to, the uncertainties inherent in the preclinical and clinical development process, including the fact that interim results may not be indicative of future results; whether Molecular Templates’ cash resources, will be sufficient to fund its continuing operations for the periods and/or trials anticipated; Molecular Templates’ ability to timely enroll patients in its clinical trials; the ability of Molecular Templates’ to protect its intellectual property rights; risks from global pandemics including COVID-19; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading “Risk Factors” in Molecular Templates’ filings with the SEC. There can be no assurance that any of Molecular Templates’ drug or biologic candidates will be successfully developed, manufactured, or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Any forward-looking statements contained in this press release speak only as of the date hereof, and Molecular Templates specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

Contacts:
Dr. Grace Kim
Head of Investor Relations
grace.kim@mtem.com



Primary Logo

Mailbox
Favorites
Level 2


MTEM
Molecular Templates Inc

Molecular Templates Inc (NASDAQ)

Search Symbol or Name

0.815
0.345 (73.40%)
Real-Time
Quote
Board
Chart
Level 2
News
Trades
OptionsNew
Public.com
Molecular Templates Announces IND Acceptance by FDA for MT-8421 ETB Program Targeting CTLA-4
March 09 2023 - 10:02AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, has received clearance by the United States Food and Drug Administration (“FDA”) following review of its Investigational New Drug Application (“IND”) to proceed for clinical testing of its novel MT-8421 ETB program targeting CTLA-4 in patients with relapsed/refractory solid tumors previously exposed to checkpoint inhibitors.
“MT-8421 represents a novel approach to target CTLA-4 in a wholly distinct manner from the current monoclonal antibody approaches. MT-8421 was designed to eliminate CTLA-4-expressing Tregs in the tumor microenvironment (“TME”) through a direct cell-kill mechanism independent of the effector cell presence that antibodies rely upon while not effecting Tregs in the periphery, the major mechanism of antibody-mediated autoimmune toxicity,” said Eric Poma, Chief Executive Officer and Chief Scientific Officer of MTEM.

Preclinical data from MT-8421 showed that in a transgenic mouse model expressing human CTLA-4 and bearing syngeneic subcutaneous tumors, MT-8421 treatment depleted immune suppressive Tregs in the TME but not in the periphery. MT-8421 was well tolerated in a non-human GLP primate toxicology study and achieved serum levels well-above projected IC50 concentrations for Tregs in the TME. MTEM expects to initiate a first-in-human phase I study with MT-8421 by mid-year 2023 at a starting dose of 32 mcg/kg.

About Molecular Templates
Molecular Templates is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. Our proprietary drug platform technology, known as engineered toxin bodies, or ETBs, leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer.

Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Molecular Templates disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Molecular Templates may identify forward-looking statements. Examples of such statements include, but are not limited to, statements regarding the safety or potential efficacy of Molecular Templates’ drug or biologic candidates; the prospects of CTLA-4 targeting therapies as a potential treatment; statements relating to the development of MT-8421; the expected timing of initiating and completing enrollment of cohorts and conducting the planned Phase I study of MT-8421; and Molecular Templates’ belief that its proprietary biologic drug platform technology, or ETBs, provides for a differentiated mechanism of action for cancer.

Forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual events or results may differ materially from those discussed in the forward-looking statements as a result of various factors including, but not limited to, the uncertainties inherent in the preclinical and clinical development process, including the fact that interim results may not be indicative of future results; whether Molecular Templates’ cash resources, will be sufficient to fund its continuing operations for the periods and/or trials anticipated; Molecular Templates’ ability to timely enroll patients in its clinical trials; the ability of Molecular Templates’ to protect its intellectual property rights; risks from global pandemics including COVID-19; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading “Risk Factors” in Molecular Templates’ filings with the SEC. There can be no assurance that any of Molecular Templates’ drug or biologic candidates will be successfully developed, manufactured, or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Any forward-looking statements contained in this press release speak only as of the date hereof, and Molecular Templates specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

Contacts:
Dr. Grace Kim
Head of Investor Relations
grace.kim@mtem.com



Primary Logo

Molecular Templates (NASDAQ:MTEM)
Historical Stock Chart
From Feb 2023 to Mar 2023 Click Here for more Molecular Templates Charts. Molecular Templates (NASDAQ:MTEM)
Historical Stock Chart
From Mar 2022 to Mar 2023 Click Here for more Molecular Templates Charts.
Latest MTEM Messages
stockguard Thu Sep 26, 2019 3:30 PM (1260 days ago)
Molecular Templates: Pipeline Progressing, Clinical Updates Loom

stockguard Mon Sep 23, 2019 12:03 PM (1263 days ago)
Is Molecular Templates (NASDAQ:MTEM) Using Too Much Debt?

frankmertens Wed Nov 14, 2018 9:57 AM (1576 days ago)
What happened ?

PithicusKong Fri Oct 26, 2018 10:27 AM (1595 days ago)
The latest subscribers at $ 5.50 must not

PithicusKong Sun Sep 23, 2018 12:01 PM (1628 days ago)
A sizable chunk of dilution coming.

ClayTrader Wed Sep 19, 2018 6:50 PM (1632 days ago)
* * $MTEM Video Chart 09-19-18 * *

PithicusKong Wed Sep 19, 2018 9:01 AM (1632 days ago)
Major news...looks like money is going to flow

PithicusKong Sat Sep 8, 2018 9:12 AM (1643 days ago)
I guess not.....

PithicusKong Thu Aug 30, 2018 2:27 PM (1652 days ago)
Looks like this is trending up again.......

PithicusKong Wed Apr 4, 2018 9:58 PM (1800 days ago)
Any opinions on Annual report? Not one post

See More Posts on MTEM Message Board
News
Press Releases
All News
FEATURED Usha Resources Announces Intention to List on the Australian Securities Exchange (ASX)
Thu Mar 09, 2023 1:23 PM (17 hours ago)
Molecular Templates Announces IND Acceptance by FDA for MT-8421 ETB Program Targeting CTLA-4
GlobeNewswire Inc. • Thu Mar 09, 2023 10:02 AM (20 hours ago)
Molecular Templates Announces Participation in Upcoming Conferences
GlobeNewswire Inc. • Wed Mar 01, 2023 4:44 PM (1 week ago)
Statement of Changes in Beneficial Ownership (4)
Edgar (US Regulatory) • Fri Feb 17, 2023 8:01 AM (3 weeks ago)
Statement of Changes in Beneficial Ownership (4)
Edgar (US Regulatory) • Fri Feb 17, 2023 8:01 AM (3 weeks ago)
Statement of Changes in Beneficial Ownership (4)
Edgar (US Regulatory) • Fri Feb 17, 2023 8:01 AM (3 weeks ago)
Amended Statement of Beneficial Ownership (sc 13d/a)
Edgar (US Regulatory) • Tue Feb 14, 2023 4:41 PM (3 weeks ago)
Amended Statement of Ownership (sc 13g/a)
Edgar (US Regulatory) • Tue Feb 14, 2023 4:30 PM (3 weeks ago)
Amended Statement of Ownership (sc 13g/a)
Edgar (US Regulatory) • Tue Feb 14, 2023 6:11 AM (3 weeks ago)
Statement of Ownership (sc 13g)
Edgar (US Regulatory) • Fri Feb 03, 2023 11:59 AM (1 month ago)
Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting
GlobeNewswire Inc. • Fri Dec 02, 2022 5:02 PM (3 months ago)
Current Report Filing (8-k)
Edgar (US Regulatory) • Fri Dec 02, 2022 8:03 AM (3 months ago)
More News Articles

Molecular Templates (NASDAQ:MTEM)
Intraday Stock Chart
Friday 10 March 2023 Click Here for more Molecular Templates Charts.

Molecular Templates: Pipeline Progressing, Clinical Updates Loom

https://seekingalpha.com/article/4293709-molecular-templates-pipeline-progressing-clinical-updates-loom

Is Molecular Templates (NASDAQ:MTEM) Using Too Much Debt?
Simply Wall St.August 29, 2019

https://finance.yahoo.com/news/molecular-templates-nasdaq-mtem-using-113015110.html

What happened ?
10-q was not that bad after all

The latest subscribers at $ 5.50 must not be very joyous.

A sizable chunk of dilution coming.

* * $MTEM Video Chart 09-19-18 * *

Link to Video - click here to watch the technical chart video

Major news...looks like money is going to flow into MTEM's coffers.

I guess not.....

Looks like this is trending up again.......

Any opinions on Annual report? Not one post in almost a full month.....Hmmmm.

Down somewhat from its recent high.....but holding its present price.

Could be a double whammy here for MTEM....the combination of Bezos, Buffet and the other guy with their revamp of health care, and the plunge in equities primarily caused by computer trading might drop this significantly. I don't know about $4 but then again there is no guarantee when computers are dictating the movement in markets.

So you mean partial bid "lots", because I was under the impression that 100 shares is one bid lot on all exchanges in the US...it's different in other countries.

those could be partial shares... watch the price, especially 4 or 5 digits after the decimal ones. Computer trading uses algorithm that can be funny to watch at times.

True...but I still cannot understand how individual trades can show up with amounts like 2, 8 or 20, and there are lots of them. How does an individual or a broker trade 2 shares?

Pith, nice consolidation at this level. Lots of good news could be coming over next few months. Been holding since pre merger THLD. Next move up with news could see 15 - 16 range. Low float here !!!

Being pushed down for a reason, or just a general lack of interest because it didn't fly to $ 20.00 Volume is low so it has to be the traders running off to lose their money somewhere else.....like an unemployed doctor......no patience.

Quiet board......doubt that that will happen, but one never knows. Really don't want to see a 'worm" of Wall St start messing with the stock.

it is a good sign that only you and me are posting here. I need it go back to about $4 pre-RS price.

This stock does not need to be "pumped".....I see it is resuming its upward momentum this morning. I have a major distain for pumpers.....worms of the investment community.

It has ben somewhat volatile......at times the price chart looks like a bucksaw blade.

I sure hope so.

Probably because it is not in pennyland......penny flippers and traders stay clear of a stock of this price. Maybe I am wrong but this is more of an investment than a short term fling.

stock went from 7-ish to 12-ish within the last 2 weeks or so and not a single post... hm.....

Update and vision for 2018 from company this AM.

TD Waterhouse knew what they were talking about. When a stock moves up like this on no news it usually portends something very positive. When they were still called Threshold it moved up on no news prior to some very promising moves and the merger.
Have been invested in Threshold in past. Looking for another entry.
Go MTEM

Getting beaten up again.......interesting, considering that T.D.Waterhouse has it as a Strong BUY.

Jeez....now I REALLY feel for the buyers above $ 11.00......too much manipulation and robot trading to make this safe yet.

News his AM...concerning first dosing.

Looks like a tug of war going on between the shorts and the believers. Today's chart look like a bucksaw blade.

That was a misprint . Meant negative article . I bought more at $8.96 think it pops next week at the conference

Jeeze....I feel for the poor buggers who bought in the $10's and $11's. Too bad the company can't step in and support the stock if it is a shorter.....that could bankrupt the dickhead and put him/her in a shelter house. What did you mean by a "beg" report, or is that just a misprint?

No news . Maybe someone is building a short position ahead of a beg report like seeking alpha. Anyway next week is healthcare conference and should see some buying . A couple hundred thousand shares is enough to move this stock up or down a point .

Board is suffering from necrosis.